Related Experiment Video

Updated: Jul 18, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Continuous subcutaneous insulin infusion (CSII) in children with type 1 diabetes

William V Tamborlane1, Kristin A Sikes, Amy T Steffen

  • 1Department of Pediatrics and General Clinical Research Center, Yale University School of Medicine, New Haven, CT, USA. WilliamTamborlane@yale.edu

Diabetes Research and Clinical Practice
|December 22, 2006
PubMed

Insights

Continuous subcutaneous insulin infusion (CSII), or insulin pump therapy, is effective for children with type 1 diabetes. It improves glycemic control and reduces hypoglycemia without compromising safety or quality of life.

Area of Science:

  • Pediatric Endocrinology
  • Metabolic Disorders
  • Diabetes Management

Background:

  • Type 1 diabetes (T1DM) management in children and adolescents requires effective strategies to achieve treatment goals.
  • Continuous subcutaneous insulin infusion (CSII) offers a potential therapeutic option for pediatric T1DM patients.

Purpose of the Study:

  • To review clinical studies on the safety and efficacy of CSII in children with type 1 diabetes.
  • To evaluate CSII as a treatment option for achieving glycemic control and reducing hypoglycemia in pediatric T1DM.

Main Methods:

  • Review of clinical studies examining CSII in pediatric populations with T1DM.
  • Analysis of data regarding glycosylated hemoglobin levels, frequency of severe hypoglycemia, safety, quality of life, and weight gain.

Main Results:

  • CSII, particularly with modern insulin analogs and pump technology, effectively reduces glycosylated hemoglobin levels in pediatric T1DM.
  • CSII therapy is associated with a decreased frequency of severe hypoglycemia in children and adolescents with T1DM.
  • Studies indicate no adverse impact on safety, quality of life, or excessive weight gain with CSII in this population.

Conclusions:

  • CSII is a safe and effective treatment modality for children and adolescents with type 1 diabetes.
  • Insulin pump therapy, in conjunction with advancements in insulin analogs and pump technology, supports the attainment of treatment goals in pediatric T1DM.
  • CSII offers significant benefits in glycemic control and hypoglycemia reduction for young patients with T1DM.

More Related Videos

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid06:21

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid

Published on: April 7, 2023

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices01:28

Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices

Parenteral drug delivery systems play a crucial role in modern therapeutics by enabling the direct administration of drugs into the systemic circulation, bypassing the gastrointestinal tract. These systems are particularly valuable for poorly absorbed oral medications that are unstable in the digestive environment or require rapid onset or sustained therapeutic levels. Delivery is achieved through intravenous, intramuscular, or subcutaneous routes, each selected based on the drug's properties...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...